

09/762649

JC02 Rec'd PCT/PTO 05 APR 2000

-0045+
ATTORNEY DOCKET NO.: 0342941-0031 (HU 01431-97)IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: President and Fellows of Harvard College
 Serial No.: PCT/US98/17691
 Filing Date: August 26, 1998
 Title: NOVEL TRANSCRIPTIONAL REGULATORS AND USES
 THEREFOR

Assistant Commissioner of Patents
 Washington, DC 20231

Sir:

Patent Application Fee Determination Sheet for National Stage Filing under 35 U.S.C. §41

Basic National Filing Fee under 35 U.S.C. §41(a)(9):

Where the Patent and Trademark Office was the International Preliminary Examining Authority
 (Small Entity): \$335.00

Additional Fees under 35 U.S.C. §§ 41(a)(13)-(15)(Small Entity):


Total Claims in Excess of 20: $(57 - 20) \times 9 = \$333.00$ Number of Independent Claims in Excess of 3: $(11 - 3) \times \$39 = \312.00

Multiple Dependent Claims: \$130.00

Total Filing Fee: \$1110.00


Enclosed is a check in the amount of \$1110.00 to cover the total small-entity National Stage Filing Fee. Please charge any additional fees, and credit any overpayments, to our Deposit Account No. 03-1721.

Respectfully Submitted,


 Brenda Herschbach Jarrell, Ph.D.
 Reg. No. 39,223


Choate, Hall & Stewart
 Exchange Place
 53 State Street
 Boston, MA 02109
 (617) 248-5000
 Dated: March 28, 2000
 Exchange.3106215.1

I hereby certify that this correspondence is being
 deposited with the United States Postal Service as first
 class mail in an envelope addressed to: Assistant
 Commissioner For Patents, Washington, D.C. 20231
 on March 28, 2000


 James A. Walsh

If any additional fees are required to be paid or if any overpayment has been made, please charge same to Deposit Account No. 03-1721.

Respectfully submitted,



Brenda Herschbach Jarrell, Ph.D.
Reg. No. 39,223

ATTORNEY FOR APPLICANT

Choate, Hall & Stewart

Exchange Place

53 State Street

Boston, MA 02109

Phone: (617) 248-5000

Fax: (617) 248-4000

Email: BHJ@choate.com

Dated: November 6, 2000

3189824_1.DOC

I hereby certify that this correspondence is being
deposited with the United States Postal Service as first
class mail in an envelope addressed to: Assistant
Commissioner For Patents, Washington, D.C. 20231
on 11-6-00

Dawn M. Nelson

ATTORNEY DOCKET NO.: 0341941-0031(HU 01431-97/BU 97-59)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jarrell et al.
Serial No.:
Filed: August 26, 1998
For: NOVEL TRANSCRIPTIONAL REGULATORS AND USES THEREFOR

VERIFIED STATEMENT (DECLARATION)
CLAIMING SMALL ENTITY STATUS
37 CFR 1.9(f) and 1.27(d)
NON-PROFIT ORGANIZATION

I hereby declare that I am an official empowered to act on behalf of the non-profit organization identified below:

NAME OF ORGANIZATION: President and Fellows of Harvard College
ADDRESS OF ORGANIZATION: 17 Quincy Street, Cambridge, MA 02138
TYPE OF ORGANIZATION:

- (X) University or other organization of higher education
- () Non-profit scientific or educational organization under a statute of a state of the United States of America
NAME OF STATE: _____
CITATION OF STATUTE: _____
- () Would qualify as tax exempt under the Internal Revenue Service Code (26 USC 501(a) and 501(c) (3) if the organization were located in the United States of America
- () Tax exempt under the Internal Revenue Service Code (26 USC 501(a) and 501(c) (3).
- () Would qualify as a non-profit scientific or educational organization under a statute of a state of the United States of America
NAME OF STATE: _____
CITATION OF STATUTE: _____

I hereby declare that the above-identified non-profit organization qualifies as a non-profit organization as defined in 37 CFR 1.9(e), for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code.

I hereby declare that rights under contract or law have been conveyed to and remain with the above-identified non-profit organization with regard to the invention titled:

TITLE: Novel Transcriptional Regulators and Uses Therefor
by:

INVENTOR(S): Kevin A. Jarrell, Samol Saha and Mark Ptashne
described in:

- ☐ the specification filed herewith
☒ U.S. Patent Application Serial Number _____
filed _____
☐ U.S. Patent Number _____
issued _____

If the rights of the above-identified non-profit organization are not exclusive, each individual, concern, or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor(s), who could not qualify as a small business concern under 37 CFR 1.9(d) or a non-profit organization under 37 CFR 1.9(e).

*NOTE: Separate verified statements are required from each named person, concern, or organization having rights to the invention, averring to their status as small entities. (37 CFR 1.27).

FULL NAME: Trustees of Boston University
ADDRESS: 108 Bay State Road, Boston, MA 02215
☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NON-PROFIT ORGANIZATION

FULL NAME: _____
ADDRESS: _____
☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NON-PROFIT ORGANIZATION

FULL NAME: _____
ADDRESS: _____
☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NON-PROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under §1001 of Title 18 of the United States Code,

and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING:

TITLE IN ORGANIZATION:

ADDRESS OF PERSON SIGNING:

President and Fellows of Harvard College
17 Quincy Street, Cambridge, MA 02138

SIGNATURE:

DS1.424761.1

DATE:

3/16/00

JOYCE BRINTON, DIRECTOR
OFFICE OF TECHNOLOGY & TRADEMARK LICENSING
HARVARD UNIVERSITY

2000-03-15 15:54

ATTORNEY DOCKET NO.: 0341941-0031(HU 01431-97/BU 97-59)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jarrell et al.
Serial No.:
Filed: August 26, 1998
For: NOVEL TRANSCRIPTIONAL REGULATORS AND USES THEREFOR

VERIFIED STATEMENT (DECLARATION)
CLAIMING SMALL ENTITY STATUS
37 CFR 1.9(f) and 1.27(d)
NON-PROFIT ORGANIZATION

I hereby declare that I am an official empowered to act on behalf of the non-profit organization identified below:

NAME OF ORGANIZATION: Trustees of Boston University
ADDRESS OF ORGANIZATION: 147 Bay State Road, Boston, MA 02215
TYPE OF ORGANIZATION:

- (X) University or other organization of higher education
- () Non-profit scientific or educational organization under a statute of a state of the United States of America
NAME OF STATE: _____
CITATION OF STATUTE: _____
- () Would qualify as tax exempt under the Internal Revenue Service Code (26 USC 501(a) and 501(c) (3) if the organization were located in the United States of America
- () Tax exempt under the Internal Revenue Service Code (26 USC 501(a) and 501(c) (3).
- () Would qualify as a non-profit scientific or educational organization under a statute of a state of the United States of America
NAME OF STATE: _____
CITATION OF STATUTE: _____

I hereby declare that the above-identified non-profit organization qualifies as a non-profit organization as defined in 37 CFR 1.9(e), for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code.

TITLE: Novel Transcriptional Regulators and Uses Therefor
by:

INVENTOR(S): Kevin A. Jarrell, Samol Saha and Mark Ptashne
described in:

- ☐ the specification filed herewith
☒ U.S. Patent Application Serial Number _____
filed _____
☐ U.S. Patent Number _____
issued _____

If the rights of the above-identified non-profit organization are not exclusive, each individual, concern, or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor(s), who could not qualify as a small business concern under 37 CFR 1.9(d) or a non-profit organization under 37 CFR 1.9(e).

*NOTE: Separate verified statements are required from each named person, concern, or organization having rights to the invention, averring to their status as small entities. (37 CFR 1.27).

FULL NAME: President and Fellows of Harvard College
ADDRESS: 17 Quincy Street, Cambridge, M A 02138
☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☒ NON-PROFIT ORGANIZATION

FULL NAME: _____
ADDRESS: _____
☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NON-PROFIT ORGANIZATION

FULL NAME: _____
ADDRESS: _____
☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NON-PROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under §1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING:

Matthew J. Burns

TITLE IN ORGANIZATION:

Assistant Treasurer

ADDRESS OF PERSON SIGNING:

Trustees of Boston University

108 Bay State Road, Boston, MA 02215

SIGNATURE:

DS1.425307.1

DATE:

3/16/00

MATTHEW J. BURNS
ASSISTANT TREASURER
BOSTON UNIVERSITY

2000 MAR 16 11:09 AM

PTO/PCT Rec'd 05 APR 2001

NOVEL TRANSCRIPTIONAL REGULATORS AND USES THEREFOR**Priority Claim**

The present application claims priority to United States provisional application
5 number 06/056,857, filed August 27, 1997, the entire contents of which are incorporated
herein by reference.

Government Support

The work described herein was supported by grants NIGHM22526, NIGHM52409,
and NSFMCB9604458 for the United States Government; the United States Government may
have certain rights in this invention.

Background of the Invention

Regulated gene expression controls cell differentiation and development. Many
15 medical disorders can be traced to errors in the control of gene expression. Much of
biological research is directed toward an understanding of the mechanisms of gene
regulation. The holy grail in these studies is the ability to control gene expression.

Very often, gene expression is regulated at the level of transcription. A great deal is
known about the machinery involved in gene transcription, and about the factors that regulate
20 it. Most transcriptional regulatory factors are proteins containing at least two functional
domains: one that binds to a specific site in DNA and one that interacts, directly or
indirectly, with some component of the transcriptional machinery to exert its regulatory
effect. These functional domains can typically be separated from one another without losing

their activities, and domains can be swapped from one regulator to another. Also, several known regulators that are naturally found in a particular organism (e.g., yeast) have been found to maintain their activity when introduced into cells of a different organism (e.g., human cells). These observations suggest that at least some transcriptional regulators employ mechanisms that have been conserved in evolution, and that work done in one organism is likely to be generalizable to others.

Despite the large database of accumulated knowledge about the transcriptional machinery and the characteristics of activators, much remains to be learned. For example, there is currently much debate over the mechanism by which regulators interact with and/or alter the activity of the transcriptional machinery. Also, there remains a need for the identification of new and different techniques for controlling gene expression.

Definitions

“Associated” -- The term “associated” is used herein to describe any physical or functional linkage between two moieties. The association may be constitutive or inducible. Moieties may be associated by covalent linkage, hydrogen bonding, van der Waals interactions, hydrophilic or hydrophobic interactions, or any other means that preserves functionality. Where polypeptide moieties are associated by covalent linkage, they form a “fusion protein”. Similarly, where nucleic acid molecules are associated by covalent linkage (e.g., by means of a 3'-5' phosphodiester bond, a 2'-5' phosphodiester bond, or some other covalent bond), they form a “fusion molecule”. Associations according to the present invention may be direct (i.e., may involve physical contact between or among the relevant moieties) or indirect (e.g., may involve one or more other compounds that mediate(s) the

interaction(s) between or among the moieties). One preferred method for producing an inducible association is to utilize a mediator molecule whose expression or production is itself inducible.

“Isolated” -- A molecule or compound is “isolated” as that term is used herein if is separated from one or more molecules or compounds with which it is associated in nature. Also, any molecule or compound that itself is never produced in nature is by definition “isolated”. Any molecule or compound that has been subjected to one or more purification steps is “isolated”. Molecules or compounds produced *in vitro* are also “isolated”. As used herein, a molecule or compound is “substantially purified” when it is at least about 90% pure.

“Moiety” -- A “moiety”, as that term is used herein, is a molecule or a portion of a molecule having a given activity or function. For example, many, if not most, known proteins that regulate transcription have at least two defined functional domains, one that directs DNA binding and one that confers regulation on genes operationally linked with a DNA site to which the protein binds. According to the present invention, the portion or portions of such a protein that are sufficient for DNA binding activity constitute a DNA binding moiety; the portion or portions sufficient for transcriptional regulation constitute a regulatory moiety. Those of ordinary skill in the art will appreciate that a moiety need not be a protein domain, nor a polypeptide of any sort. Any molecule, or collection of molecules, having the designated activity can constitute a moiety according to the present invention.

“Non-naturally occurring” -- The phrase “non-naturally” occurring, when applied to RNA molecules herein, refers to RNA molecules that i) have a nucleotide sequence that is not found in the organism in which they are active; and/or ii) are in a form that is not found in nature. For example, an RNA molecule whose complete nucleotide sequence (i.e., the

sequence of the whole molecule) is not found within any natural RNA molecule endogenous to the cell in which the RNA is activating transcription is non-naturally occurring according to the present definition. Also, any RNA molecule that contains one or more sequence elements that are not naturally found in that cell is a non-naturally occurring RNA molecule.

5 A "sequence element", as used herein, is any portion of an RNA molecule's sequence. All RNA molecules contain one or more sequence elements (since a single "A", "U", "G", or "C" is a sequence element); non-naturally occurring RNAs of the present invention are distinguished by having one or more sequence elements that are not found in naturally-occurring RNAs in the cell in which the non-naturally occurring RNA is active. Alternative
10 non-naturally occurring RNAs are those that, though their nucleotide sequence may be identical to that of an RNA found in nature, are in a form not found in nature. For example, any "isolated" RNA is non-naturally-occurring. Also, any RNA molecule that has been modified so that it includes one or more chemical groups not found in naturally-occurring RNAs of the same sequence, or lacks one or more chemical groups naturally found in RNAs
15 of the same sequence is non-naturally occurring according to the present invention.

"Operationally linked" -- The phrase "operationally linked", as used herein to describe a site in a nucleic acid, means that the site is located in three-dimensional space in a position and orientation that allows a regulator binding to the site to exert its effects on transcription. As is known in the art, transcriptional regulatory sites are commonly linked by
20 covalent association to the promoter whose expression they regulate. That is, regulator sites are typically part of the same DNA molecule as the promoter. In most cases, such sites are located upstream of the promoter, though examples of regulatory sites that are effective when positioned downstream of the promoter, either within or downstream of the gene, are known.

According to the present invention, covalent linkage is not essential for operational linkage between a regulatory site and a promoter. A regulatory site for use in accordance with the present invention may be operationally linked to a promoter, for example, by being provided as a separate DNA molecule or by being embedded within the transcript whose expression the promoter directs.

Summary of the Invention

The present invention provides novel transcriptional regulators comprised of ribonucleic acid (RNA). The RNA regulators of the present invention alter the rate and/or the extent of transcription from a promoter when they are delivered to a site that is operationally linked to that promoter. Those inventive RNA regulators that increase the rate or level of transcription from a given promoter are termed "riboactivators"; those that decrease the rate or level of transcription are termed "riborepressors". Preferred RNA regulators of the present invention are capable of association with a DNA binding moiety characterized by an increased affinity for a particular DNA site as compared with DNA generally. Particularly preferred regulators are characterized by an ability to interact specifically with a TATA-binding protein (TBP) present in the cells in which they are active. Certain preferred riboregulators have a nucleotide sequence that includes a region conforming to the consensus 5'-UGC(G>U>A)GG(U>A>C)(U>ACG)(C>A)(G>A>U)-3' (SEQ ID NO:4).

Description of the Drawings

Figure 1 presents the Wickens/Fields three-hybrid system for identifying proteins that interact with known "bait" RNAs.

Figure 2 presents an inventive two-hybrid system utilized to identify riboactivators.

Figure 3 presents a Northwestern blot demonstrating a specific interaction between riboactivator number 7 and yeast TBP.

Figure 4 presents a Northwestern blot demonstrating that riboactivator number 7 binds to yeast TBP (lane 3), but not to yeast TFIID lacking TBP (lane 4), to mammalian TFIID (lane 2), or to Yeast RNA polymerase II holoenzyme (lane 5).

Description of Certain Preferred Embodiments of the Invention

Riboregulators

Any RNA molecule, or portion of an RNA molecule, that alters transcription from a promoter when recruited to a regulatory site operationally linked with that promoter is a riboregulator of the present invention. Both riboactivators and riborepressors are encompassed within the present invention. Preferred riboregulators affect transcription initiation, but RNAs that affect elongation, reinitiation, termination, and/or pausing are also included within the present invention.

Preferred riboregulators of the present invention are active *in vitro* and/or *in vivo*. Preferably, the riboregulators are active in one or more cell types selected from the group consisting of bacterial cells, yeast cells, mammalian cells, insect cells, plant cells, reptile cells, celenorate cells, and protozoan cells. Particularly preferred riboregulators are active in yeast, mouse, and/or human cells. Preferred riboregulators of the present invention are active at more than one promoter in a particular cell (i.e., affect transcription at various promoters

when recruited to sites operationally linked to those promoters). Particularly preferred riboregulators are active both *in vivo* and *in vitro*.

According to the present invention, preferred riboregulators affect transcription by the same molecular mechanism utilized by one or more naturally-occurring protein factors that regulate transcription. For example, one class of naturally-occurring transcriptional activators, known as “acidic activators”, is thought to stimulate transcription by contacting one or more components of the general transcription machinery and recruiting that machinery to the promoter. Although the details of this mechanism are not well understood, a “squenching” assay has been developed to identify activators that fall within this mechanistic category. The term “squenching” refers to the fact that, when a transcriptional activator is expressed at high levels in a cell in which it is active, the effect may be to reduce gene transcription in that cell, sometimes even to the point of killing the cell. Current models explain this observation by hypothesizing that non-DNA-bound molecules of the highly-expressed activator compete with DNA-bound activators for interaction with the same target or targets in the general transcription machinery, so that there is less target available for interaction with DNA-bound activators, the transcription machinery is recruited to promoters less frequently, and transcription is therefore reduced. For purposes of the present invention, any riboactivator that squenches a known acidic activator is classified as one that works by the “acidic activator mechanism”. Preferred riboactivators of the present invention squench, or are squenched by, Gal4 when expressed in yeast and/or in mammalian cells.

In certain preferred embodiments of the invention, the riboregulator includes a stem-loop structure. Particular embodiments of preferred stem-loop containing riboregulators are described in Example 2.

Riboregulators of the present invention may be constitutively active or may alternatively be active only under specified conditions. For example, the techniques and methods described herein may readily be employed to select riboregulators that exert their effects on transcription only in the presence (or absence) of a chemical molecule, a modification enzyme (e.g., a methylase), and/or some component of the growth medium. Riboregulators that are active only in the presence (or absence) of antibiotics may be particularly easy to identify since several RNA-binding antibiotics are known. The techniques of the present invention may also be employed to identify, for example, temperature-sensitive riboregulators. All such conditional riboregulators are encompassed within the scope of the present invention.

DNA binding moieties

As discussed above, inventive riboregulators are RNA molecules that alter the rate or extent of transcription from a promoter when recruited to a regulatory site operationally linked to that promoter. Typically, such recruitment is accomplished by association with a DNA binding moiety. Any chemical compound may be utilized as a DNA binding moiety providing that it has sufficient affinity for DNA to recruit the riboregulator to a regulatory site and also has the ability to form an association with the riboregulator. For example, nucleic acids, polypeptides, intercalation compounds, and/or any chemical compounds that bind to DNA may be utilized as DNA binding moieties. Preferably, the DNA binding moiety is characterized by an increased affinity for a particular regulatory site as compared in DNA generally, so that the DNA binding moiety is said to display sequence-specific DNA binding as that term is understood in the art.

The preferred means by which the riboregulator is associated with the DNA binding moiety depends on the chemical nature of the moiety. For example, where the DNA binding moiety is a DNA or RNA molecule, the riboregulator may be associated with the moiety through covalent linkage (e.g., via a 3'-5' or a 2'-5' phosphodiester bond). In certain preferred embodiments, the riboregulator is produced as a single RNA molecule with the DNA binding moiety. Alternatively, the riboregulator may be associated with a nucleic acid DNA binding moiety through base-pair interactions or other three-dimensional nucleic acid interaction. Where the DNA binding moiety is a polypeptide or a chemical compound, the riboregulator may be covalently linked to the moiety, but is preferably associated by non-covalent interaction.

Applications

Those of ordinary skill in the art will recognize that the riboregulators of the present invention are useful in a wide variety of contexts. For example, they are useful tools in the efforts to understand the mechanism of gene regulation. They are also useful as reagents for identifying and dissecting RNA-RNA and RNA-protein interactions. Furthermore, the inventive riboregulators are useful as agents for controlling gene expression. In one particular embodiment of the present invention, the inventive riboregulators may be used as therapeutic agents to modulate gene expression *in vivo* in order to alleviate or correct a disease state. Certain preferred embodiments of these applications are discussed in more detail below.

Experimental tools

Much effort in the field of transcriptional regulation has been directed toward the identification of the interaction target for the protein regulators that activate and repress transcription *in vivo*. The riboregulators of the present invention provide valuable new tools for this endeavor. Riboregulators that act by the same mechanism as natural transcriptional regulators are particularly useful in this regard. One advantage of riboregulators, as compared with protein factors, for these types of studies is that a variety of RNA-specific techniques are available that can be employed to identify and characterize any interaction partners. For example, riboregulators can be readily cross-linked to any interaction target or targets with which they physically interact. Techniques for cross-linking single-stranded RNAs with nearby proteins are well known in the art. Techniques for cross-linking double-stranded RNAs, which techniques are useful for riboregulators containing stem-loop or other double-stranded secondary structures, have recently been developed (see, for example, Liu et al., in Abstracts of Papers Presented at the 1997 Meeting on Eukaryotic mRNA Processing, Cold Spring Harbor Laboratory, August 20-24, 1997, pg. 82). Other useful RNA-specific techniques include, for example, Northwesterns, gel mobility shift assays, filter binding assays, etc. (see Example 4). Also, complexes containing an RNA molecule can be detected by reverse transcription and amplification.

Riboregulators of the present invention may also be used in novel multiple-hybrid experiments to identify RNA or protein molecules that interact with particular test RNAs. Most available di-hybrid or multiple-hybrid systems rely on protein components and are not readily adaptable to analysis of RNA-RNA interactions. Even RNA-protein interactions are often difficult to study with current systems; only the Wickens system has been developed for that purpose. The inventive demonstration of activating RNAs, however, allows ready

production of multiple-hybrid systems that can analyze RNA-RNA and RNA-protein interactions. For example, the test RNA can be produced as a single hybrid molecule with the riboactivator and then screened against either a protein library fused to a DNA binding domain (a two-hybrid system) or an RNA library fused to an interaction moiety that allows the RNA library to be recruited to DNA (a three-hybrid system). Without a riboregulator, RNA-RNA interactions could only be studied in "four-hybrid" systems, an impractical, if not infeasible arrangement.

Inventive riboregulators may also be employed in multiple-hybrid experiment to identify RNAs that interact with a test protein. In the simplest version of this experiment, the test protein is fused to a DNA binding domain and an RNA library is fused with the riboregulator. Such studies can lead to the development of "RNA linkers" that can be used to bring any two proteins together. That is, once RNAs are identified that interact with first and second proteins, those RNAs are attached to one another (preferably by producing both linked together as a single RNA molecule) to produce an RNA linker. Such RNA linker molecules, although not necessarily riboregulators, are also within the scope of the present invention.

Therapeutic reagents

A large number of medical problems are caused by over- or under-expression of a particular gene, or by mutation of a gene. Many more can be alleviated by increased or decreased gene expression. The inventive riboregulators, which can be specifically targeted to activate or repress a selected gene, are useful as therapeutic agents.

For example, metastatic prostate cancer is currently treated with two drugs, leuprolide, which blocks testosterone production, and flutamide, which acts as an androgen receptor antagonist. These drugs are effective against prostate cancer because prostate cancer cells require hormone stimulation to grow and divide. Unfortunately, these drugs lose their effectiveness after about two years of treatment because resistant cancer cells arise. It is known that at least 80% of these resistant cells express the androgen receptor. Moreover, these cells become resistant to leuprolide and flutamide either by amplifying the androgen receptor gene so that much more receptor is made or by mutating that gene so that the receptor it produces is capable of stimulating cell proliferation even when it is not bound to a hormone ligand. According to the present invention, an improved method of treatment for prostate cancer would involve administration of an agent that represses the androgen receptor gene. Such an agent could be given alone or in combination with leuprolide and/or flutamide. An inventive riborepressor is such an agent. Preferably, the riborepressor is prepared in association with a DNA binding moiety that targets it to a regulatory site that is operatively linked to the androgen receptor gene. Alternatively or additionally, the riboregulator may be associated with an interaction moiety that mediates an association between the riboregulator and a DNA binding entity endogenous to the cells to which the riboregulator is delivered. The riboregulator is packaged into a pharmaceutical formulation according to known techniques and procedures, and is preferably delivered orally.

As but one more example, inventive riboregulators are useful in the treatment of anemia and other disorders related to erythrocyte production. Erythropoietin (Epo), a protein agent that stimulates production of erythrocytes, is perhaps the most successful drug produced through biotechnology. Recent studies have shown that it is possible to make Epo

even more effective by co-administration of an agent, known as interleukin-1, that increases transcription of the erythropoietin receptor (EpoR). Unfortunately, interleukins have proven not to be generally useful as pharmaceutical agents because of their associated toxicities.

The present riboactivators provide an alternative agent that could be used to stimulate EpoR gene expression. Because inventive riboactivators can be designed to be highly specific to the particular gene to be activated, they should not have the toxicity problems associated with interleukins, which have broad-ranging activities.

It is appreciated that the structure of the inventive riboregulators may have to be modified in order to ensure their effectiveness as therapeutic agents. It may be necessary, for example, to increase the stability of the riboactivator in order to ensure that it persists long enough *in vivo* to have a significant effect on gene expression. It is known that addition of 2'-O-methyl or-phosphorothiol groups increases the stability of RNA molecules *in vivo*. Also, circularized versions of the molecules may be more stable. Other modifications might be made in order to increase bioavailability of the riboregulators, and/or to increase the extent to which they are taken up by cells. Those of ordinary skill in the art will appreciate that any of a wide variety of modifications may readily be tested, and the resultant modified RNAs can be assayed as described herein to ensure that they retain their functionality.

Examples

Example 1

A Screen for the Identification of Riboregulators

We have developed a novel two-hybrid transcriptional regulation system for use in the identification of riboregulators. In order to simplify the presentation of our system, we

first describe a prior art system that was prepared by Wickens and Fields to allow the identification of proteins that interact with known RNAs (SenGupta et al., *Proc. Natl. Acad. Sci. USA* 93:8496, 1996).

The Wickens/Fields system, which is depicted in Figure 1, utilizes i) a first hybrid 100 comprising a DNA binding moiety 200 (the lexA DNA binding domain) fused to an RNA binding moiety 300 (the MS2 coat protein); ii) a second hybrid 400 comprising a recruiting RNA 500 (the MS2 RNA) fused to the bait RNA 600; iii) and a third hybrid 700 comprising a target protein 900 fused to a transcriptional activation domain 900 (the Gal4 activation domain). The DNA binding moiety 200 recognizes a site 1000 positioned upstream of a reporter gene 1100 and recruits the bait RNA 600 to that site because of the interaction between the RNA binding moiety 300 and the recruiting RNA 500; transcriptional activation results when the bait RNA 600 interacts with the target protein 700, so that the transcriptional activation domain 800 is brought to the DNA. As with other known two-hybrid (or multi-hybrid) transcriptional activation assay systems, the Wickens/Fields system is designed to screen protein libraries (specifically, libraries of target proteins) to identify those with a desired interaction capability (i.e., the ability to interact with the known bait RNA).

We have modified the Wickens/Fields system as shown in Figure 2. Our system employs only two hybrids, one 100 comprising a DNA binding moiety 200 fused to an RNA binding moiety 300, and one 400 comprising a recruiting RNA 500 linked to a bait RNA 600 (the riboregulator). In this system, the bait RNA 600 is recruited to the DNA because of the interaction between the RNA binding moiety 300, which itself is bound to DNA because of its linkage to the DNA binding moiety 200, and the recruiting RNA 500; transcriptional

activation results whenever the bait RNA **600** is a riboactivator; transcriptional repression results when the bait RNA **600** is a riborepressor.

The inventive system depicted in Figure 2 differs from the Wickens/Fields system in at least two major ways: i) it does not rely on a third hybrid, containing a transcriptional activation domain, to mediate transcriptional regulatory effects but rather detects transcriptional regulation directed by the bait RNA itself; and ii) the bait RNA is a library of RNA molecule from which active RNAs are identified, rather than a known RNA that is used to identify active interacting proteins.

In the particular embodiment of the inventive system that is depicted in Figure 2, the DNA binding moiety **200** consists of a lexA DNA binding domain; the RNA binding moiety **300** is the MS2 protein; and the recruiting RNA **500** is the MS2 RNA. In light of the above discussion, those of ordinary skill in the art will appreciate that each of these system components could readily be substituted with a different molecule (or group of molecules) that performs substantially the same function. For example, any molecule or compound that is capable of both (i) specific recognition of a DNA sequence and ii) interaction with an RNA binding moiety, when utilized under the conditions of the assay, is useful as a DNA binding moiety in accordance with the present invention.

Also, any of a variety of molecules or compounds may be utilized as RNA binding moieties and recruiting RNAs in place of the MS2 protein and MS2 RNA depicted in Figure

2. Useful RNA binding moieties must interact specifically with both the DNA binding moiety and the recruiting RNA under the conditions of the assay; useful recruiting RNAs must interact specifically with the RNA binding moiety and the bait RNA.

Any of a variety of different genes may be utilized as reporter genes, so long as their gene products are detectable. In screens for riboactivators, it is generally preferred that the RNAs be tested for their ability to activate at least one reporter gene that is an essential gene under the conditions of the assay (so that the assay is a selection, rather than a screen). In screens for riborepressors, it is preferred that the RNAs be tested for their ability to repress a gene whose expression is toxic under the conditions of the assay. In such assays, it may also be desirable to arrange that the cell's sensitivity to the toxic gene be inducible, in order to avoid the problem of the cell being killed by expression of the gene before the potential riborepressors have had the opportunity to exert their effects.

When using the screen depicted in Figure 2, an RNA is identified as a riboregulator if it exerts any reproducible effect (increase or decrease beyond that expected error) on transcription. Preferred riboactivators increase or decrease gene expression by at least 2-fold, preferably at least 5-fold, more preferably at least 10-20 fold, yet more preferably at least 100 fold, at most preferably at least 1000 fold.

Example 2

Identification and Characterization of Riboactivators from an "R10" Library

Materials and Methods

STRAINS AND MEDIA: The *L40*-coast yeast strain (a derivative of the *ura3 L40* strain containing the *lexA*-MS2 fusion protein integrated into the genome; *MATa*, *ura3-52*, *leu2-3*, *-112*, *his3Δ200*, *trp1Δ1*, *ade2*, *LYS2::(lexA-op)-HIS3*, *ura3::(lexA-op)-LacZ*, *LexA-MS2 coat protein (TRP1)*) was generously provided by Marvin Wickens. Rich (YPD) and synthetic (S)

media were prepared as described by Rose et al. (*Methods in Yeast Genetics*, Cold Spring Harbor Press, Cold Spring Harbor, NY, 1990).

CONSTRUCTION OF THE R10 LIBRARY: An oligonucleotide, called "Oligo2" that included a 15nt stem-loop and a randomized 10-mer loop was synthesized. Oligo 2 had the sequence 5'-

CTCTGGGAGCTGCGATTGGCAGAATTCCGGCTAGAACTAGTGGATCCCCCGGGCG
AGGCTTATCCNNNNNNNNNNNGGATGTGCTGACCCCGGGCAGCTTGCATGCCTGC
AGGTCGACTCTAGAAAACATGAGGATCACCC (SEQ ID NO:1). Two other
oligonucleotides, "Oligo 1" and "Oligo 3" were also prepared. The sequences of these
oligonucleotides were selected so that they could be used to amplify Oligo 2 to produce a
template library that, when transcribed, would produce the "R10" library of RNA molecules.
Oligo 1 and Oligo 3 had the following sequences: 5'-CTCTGGGAGCTGCGATTGGC (SEQ
ID NO:2) and 5'-GGGTGATCCTCATGTTTTCT (SEQ ID NO:3), respectively.

Oligo 2 was amplified in ten simultaneous polymerase chain reactions utilizing 72 uL
water, 109 uL 10 X PCR buffer (Promega), 4 uL magnesium chloride (Promega, 2 uL
nucleotide mix (10 mM each), 3 uL Oligo 1 (500 ng/uL), 3 uL Oligo 3 (500 ng/uL), 5 uL
Oligo 2 (50 ng/uL), and 1 uL Taq DNA polymerase each. Following one cycle of 5 minutes
at 94 °C, 2 minutes at 50 °C, and 3 minutes at 72 °C, thirty cycles of 1 minute at 94 °C, 2
minutes at 50 °C, and 3 minutes at 72 °C were performed. A final 10 minute extension
reaction at 72 °C was then performed. Products were purified over a G25 spin column and
were ethanol precipitated. Products were then resuspended in sterile 1 X TE, to a final
volume (from all 10 reactions) of 100 uL.

YEAST TRANSFORMATION. Yeast transformation was performed by the lithium acetate method (Rose et al., *Methods in Yeast Genetics*, Cold Spring Harbor Press, Cold Spring Harbor, NY, 1990), exploiting the gap repair phenomenon described by Rothstein (*Methods Enzymol*, 194:281, 1991). 1 µg, 5 µg, 10 µg, or 20 µg of R10 library PCR product were introduced into yeast cells in combination with Smal-cut pIII/MS2 vector.

Transformants were selected on S media lacking the appropriate amino acids.

X-GAL PLATE SCREEN: Transformants were grown on white nitrocellulose filters placed on an appropriate selective medium. Subsequently, the filters were transferred to a synthetic medium containing 2% glycerol and 50 µg/ml x-gal. Pale blue to dark blue colonies were identified, the plasmids they contained were isolated according the known procedures (Ward, *Nuc. Acids Res.*, 1990), and the isolated plasmids were retransformed into the same strain and were retested for transcriptional activation activity.

LIQUID β-GALACTOSIDASE ASSAYS: Transformants that turned blue on the X-gal plate screen were grown to an OD₆₀₀ of between 1.0 and 2.0 in 5 mls of selective media containing 2% glucose. β-galactosidase activity was assayed as described (Rose et al., *Methods in Yeast Genetics*, Cold Spring Harbor Press, Cold Spring Harbor, NY, 1990); units of activity were calculated as nmol/min/mg protein. Each assay was performed at least in duplicate on several occasions.

CONSTRUCTION OF STRAIN FOR GAL4-MS2 EXPERIMENTS: A blaster plasmid (Alani et al., *Genetics* 116:541, 1987) was utilized to disrupt the *TRP* gene of the GGY1 strain (Gill et al., *Nature* 334:721, 1988) by integration of the *URA3* gene. *URA3* gene was deleted by recovering yeast colonies that could grow on plates including 5-FOA.

PRODUCTION OF KEENE RNA-MS2 FUSION: We ordered two oligonucleotides, Keene-1 (5'-CCGGGCGAGGCTTATCCTGGTGGAGCAGGATGTGCTGACC; SEQ ID NO:18) and Keene-2 (5'-CCGGGGTCAGCACATCCTGCTCCACCAGGATAAGCCTCGC; SEQ ID NO:19). These oligos were annealed to one another and were cloned into the *Xma*I site of pMS2-2 (SenGupta et al., *Proc. Natl. Acad. Sci. USA* 93:8496, 1996). A number of clones were sequenced; one clone that had insert in the proper orientation was tested for transcriptional activation capability in yeast.

PRODUCTION OF TAR-MS2 FUSION: We ordered two oligonucleotides, Tar-1 (5'-CCGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGA GAAC; SEQ ID NO:20) and Tar-2 (5'-CCGGGTTCTCTAGTTAGCCAGAGAGCTCCCAGGCTCAGATCTGGTCTAACCAGAG AGAC; SEQ ID NO:21). These oligos were annealed to one another and were cloned into the *Xma*I site of pMS2-2 (SenGupta et al., *Proc. Natl. Acad. Sci. USA* 93:8496, 1996). A number of clones were sequenced; one clone that had insert in the proper orientation was tested for transcriptional activation capability in yeast.

PRODUCTION OF NUMBER 5-TAR STEM-MS2 FUSION: We ordered two oligonucleotides, 5/Tar-1 (5'-CCGGGTCTCTCTGGTTAGACCAGATCTGAGCCGGGATGCTCTCTGGCTAACTAGA GAAC; SEQ ID NO:22) and 5/Tar-2 (5'-CCGGGTTCTCTAGTTAGCCAGAGAGCATCCCGGCTCAGATCTGGTCTAACCAGAG AGAC; SEQ ID NO:23). These oligos were annealed to one another and were cloned into the *Xma*I site of pMS2-2 (SenGupta et al., *Proc. Natl. Acad. Sci. USA* 93:8496, 1996). A

number of clones were sequenced; one clone that had insert in the proper orientation was tested for transcriptional activation capability in yeast.

FUSION OF NUMBER 7 LOOP TO 6-BASE PAIR *Sma*I STEM: We ordered two oligonucleotides, 7/*Sma*-1 (5'-CCGGGTGCTGGATCAC; SEQ ID NO:24) and 7/*Sma*-2 (5'-CCGGGTGATCCAGCAC; SEQ ID NO:25). These oligos were annealed to one another and were cloned into the *Xma*I site of pMS2-2 (SenGupta et al., *Proc. Natl. Acad. Sci. USA* 93:8496, 1996). A number of clones were sequenced; one clone that had insert in the proper orientation was tested for transcriptional activation capability in yeast.

Results

In designing our riboactivator screening system, we first considered what length RNA we should screen. In order to answer this question, we considered what is known about RNA structure and protein-RNA interactions. One experimental system that has provided a significant amount of information about the probability that random RNAs will assume structures, and also about certain characteristics of protein-RNA interactions, is the Systematic Evolution of Ligands by Exponential Enrichment (SELEX) system developed by Larry Gold and colleagues (reviewed in Gold et al., *Annu. Rev. Biochem.* 64:763, 1995). In this system, libraries of random nucleic acid molecules are synthesized *in vitro* and are screened, also *in vitro*, for their ability to interact with high affinity with particular targets. A sufficient number of SELEX experiments has been described to support the generalization that RNA transcripts with random base compositions are likely to assume some structure is they are at least 25 nucleotides long. These experiments have also shown that proteins that bind to 25 nt-long RNAs tend to interact with about 10-15 nts of the RNA. Although nothing

in these experiments indicates that RNAs *must* be 10-25 nt long to have secondary structure, or to have protein binding capability, we decided to utilize RNAs within this size range in our original screen.

In one particular SELEX experiment, researchers produced a library of RNA stem-loops and screened it to identify those that bind to an antibody at the antigen recognition site (Tsai et al., *Proc. Natl. Acad. Sci. USA* 89:8864, 1992). The RNA library was produced by inserting a random RNA 10-mer between two complementary sequences that could form a stable base-paired stem. Thus, all of the RNA molecules in the library contained the same stem. In some cases, the inserted 10-mer probably included additional self-complementary nucleotides, so that the stem was further extended; in others, the 10-mer probably remained as a loop.

Although it was clearly not our only option, we chose to utilize a stem-10mer-loop strategy analogous to that described above in our initial screen for riboactivators. We prepared a library of RNA molecules, termed the "R10 library" that each comprised two 15-nt complementary sequences flanking a random 10-mer RNA. Use of this library was attractive for two reasons. First, because the random RNA in the library is relatively short in sequence, it is feasible to screen every possible molecule. Also, it has been reported that 10 nt is the maximum size for an RNA loop *in vivo* (Wyatt et al. in *The RNA World* (Gestekand et al., eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., pp. 465-496, 1993). Thus, when expressed *in vivo*, this library is likely to contain molecules with a variety of different stem-loop structures, ranging from structures with the minimum allowable loop size (thought to be 2 nt; Wyatt et al. in *The RNA World* (Gestekand et al., eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., pp. 465-496, 1993) to the maximum

allowable loop size (10 nt). Presumably, bulged nucleotides are also not uncommon in the R10 library. Given that many RNA binding proteins recognize portions of RNA molecules that include loops or bulges (Draper, *Annu. Rev. Biochem.* 64:593, 1995), we expected that many molecules in the R10 population would be capable of interacting with proteins.

5 We transformed the R10 library into yeast, relying on the gap-repair method to integrate the library into a co-transformed plasmid containing the MS2 RNA so that, hybrid RNAs containing potential riboactivators linked to the MS2 RNA were produced *in vivo*. The yeast strain into which we transformed the library contained a gene for the *lexA*-MS2 fusion protein integrated in its genome, and also contained two different reporter genes, *HIS3* and *LacZ*, each of which is linked to a LexA operator. Transformants that contained riboactivators were selected for their ability to grow on a synthetic medium lacking histidine (i.e., for their ability to express *HIS3*). Aminotriazole, a competitive inhibitor of the *HIS3* gene product, was added to the medium to increase the stringency of the selection. Of approximately 8 million transformants, only approximately 200 expressed sufficient levels of
15 *HIS3* to survive on the selective medium.

These 200 His⁺ transformants were screened to identify those that also expressed elevated levels of β -galactosidase; 12 were chosen as candidates after analysis by plate assay. Plasmids were isolated from these 12, were re-transformed into the same strain, and were re-assayed to ensure that the observed transcriptional activity was linked to the plasmid and did
20 not reflect spurious mutation of the strain. 8 of these re-transformants proved to be plasmid-linked. We quantified the levels of activation that we were detecting by performing liquid β -galactosidase assays. We also isolated the plasmids from these 8 colonies and determined the nucleotide sequence of the RNAs they encoded. The β -galactosidase values and loop

sequences of our 8 positive clones are presented below in Table 1. As can be seen, there was a strong consensus of 5'-UGC(G>U>A)GG(U>A>C)(U>ACG)(C>A)(G>A>U)-3' (SEQ ID NO:4) among the activating RNAs.

TABLE 1		
RIBOACTIVATOR ISOLATE NUMBER	SEQUENCE	β -GALACTOSIDASE
control (no insert)		0.2
1	5'-UGCGGGUACG SEQ ID NO:5	23.0
2	5'-UUGCUGGCGA SEQ ID NO:6	22.0
3	5'-UGCGGGUCAU SEQ ID NO:7	40.0
4	5'-UGCGGGUUCG SEQ ID NO:8	32.0
5	5'-UGCGGGAUCA SEQ ID NO:9	56.0
6	5'-UGCAGGUUCG SEQ ID NO:10	70.0
7	5'-UGCUGGAUCA SEQ ID NO:11	87.0
8	5'-UUGCUGGCGA SEQ ID NO:12	33.0

In performing our sequencing studies, we found that several of our riboactivating RNAs had alterations in sequences outside of the engineered stem-loop structure. Specifically, riboactivators numbered 3, 5, 6, and 7 had a deletion of a sequence element that is normally repeated in the MS2 RNA. Riboactivator number 7 also had a single base substitution (C to T) 15 nucleotides downstream of the stem-10bp structure.

We also sequenced eight non-activating RNAs in order to be sure that our library was not biased and that our riboactivator consensus truly reflected transcriptional regulatory activity rather than some other aspect of the library. Certain exemplary non-activator loop sequences are presented below:

TABLE 2	
CONTROL RNA ISOLATE NUMBER	SEQUENCE
3	5'-CACGGTAAGT SEQ ID NO:13
6	5'-CAAAGACAGG SEQ ID NO:14
8	5'-GGCTGGTGGT SEQ ID NO:15
10	5'-GTAGAGCGA SEQ ID NO:16

Having identified our consensus sequence, we noticed that two known RNAs, the HIV Tar RNA and the RNA described above that was identified as having the ability to bind to an antibody raised against a particular 13-amino-acid peptide (Tsai et al., *Proc. Natl. Acad. Sci. USA* 89:8864, 1992), have similar nucleotide sequences to our consensus. Each of these RNAs has a stem-loop structure. The Tar loop is similar to our consensus but its stem is unrelated; the stem of the other RNA, which we refer to as the "Keene RNA", is identical to ours but its loop is less similar to our consensus than is Tar's. We tested whether either HIV Tar or the Keene RNA act as a riboactivator in our system. We also tested whether our riboactivator number 5 would retain its activation capability when positioned atop the Tar stem.

We found that neither Tar nor the Keene RNA activated transcription in our system. We further found that riboactivator number 5 retained significant activation capability when positioned atop the Tar stem. Table 3, below, summarizes our results with Tar.

TABLE 3			
RNA	STEM SEQUENCE	LOOP SEQUENCE	β -GAL
vector	--	--	0
number 5	G-C U-A	CGGGAU	60
Tar	C-G G-C	CUGGGA	1
number 5 on Tar stem	C-G G-C	CGGGAU	20

We also tested whether riboactivator number 7 would retain its activity when positioned atop a different stem. Specifically, we placed the number 7 loop at the top of a 6-basepair stem comprising a *Sma*I site. As shown below in Table 4, we found that riboactivator number 7 retained significant activation capability when presented at the top of this *Sma*I stem.

TABLE 4	
RNA	β -GALACTOSIDASE
number 7	80
number 7 on <i>Sma</i> I stem	40
control	0.1

In order to confirm that our riboactivators were working as expected, we transformed them into a control strain lacking the *lexA*-MS2 hybrid and confirmed that, in the absence of this hybrid (which is required to recruit the riboactivators to the DNA), the *LacZ* gene was not activated.

We performed three different experiments to ensure that our RNA molecules were responsible for the activation that we were observing. First, we re-cloned the 40 basepair segment encoding activators 7 and 5 into a fresh vector (containing both copies of the MS2 repeat and also lacking the base substitution that was present in original activator number 7) and confirming that the re-cloned activators retained transcriptional regulatory activity. Next, we re-cloned activators 5 and 7 in the "wrong" orientation and established that such "reverse" activators did not stimulate transcription. Finally, we made sure that our riboactivators could stimulate transcription when recruited to DNA by a DNA binding moiety other than the *lexA* DNA binding domain.

Specifically, we introduced the plasmids encoding our riboactivator/MS2 binding domain RNAs into a strain expressing a Gal4-MS2 hybrid and containing a reporter gene in which 5 Gal4 operators were positioned upstream of the *LacZ* gene. In this experiment, as shown below in Table 5, we found that our riboactivators gave the following levels of β -galactosidase expression:

TABLE 5	
RIBOACTIVATOR ISOLATE NUMBER	β -GALACTOSIDASE
control (no insert)	20
1	43
2	38
3	37
4	42
5	58
6	58
7	75
8	46

In order to test whether our riboactivators functioned as "acidic activators", we re-transformed isolate number 7 into the L40 coat strain in combination with either a control vector (pFL46L) or a vector over-expressing Gal4 (pSS272-3). We tested the expression of the *LacZ* gene in the restraint strains by liquid β -galactosidase assay and found the following:

TABLE 6	
STRAIN	β -GALACTOSIDASE
control	30
Gal4 overexpression	9

As can be seen, our riboactivator was squelched by Gal4.

We also wanted to determine whether our riboactivators had sequences that were present elsewhere in the yeast genome. Since the entire yeast genome has been sequenced, this question can be answered definitively with a simple computer database search. We searched with both the exact sequence and its reverse complement for riboactivator number 7. The exact sequence was present in 12 locations, one of which was the *SWI1* gene, which encodes a component of the SWI/SNF global transcription activator complex. The reverse complement was present at 14 locations. Other riboactivator sequences were also found in the yeast genome, as summarized below in Table 7.

TABLE 7				
ACTIVATOR	GENE NAME	ACCESSION NO.	GENE FUNCTION/ STRUCTURE	ACTIVATOR SEQUENCE LOCATION
1	ALD7	Z75282	aldehyde dehydrogenase	151 nt from end of ORF

1	SEN3	Z37993	26s proteasome regulatory subunit	1685 nt from beginning of ORF; 1149 from end
2	YML093w	Z46660	similar to <i>P. falciparum</i> liver stage antigen LSA-1	421 nt from end of ORF
2	YMR006c	Z49810	hypothetical protein contains prenyl group binding (CAAX box)	1477 nt from end of ORF
2	YOR144c	Z75052	weak similarity to human DNA binding protein PO-GA	1070 nt from start of ORF
3	YOR064	Z74972	weak similarity to human retinoblastoma binding protein 2	89 nt past ORF
3	YBR044c	Z35913	similar to chaperonin HSP60 proteins	634 nt from start of ORF
4	PIE2	Z75017	phosphatidylinositol phosphate phosphatase; transmembrane	1489 nt from end of ORF
4	YOR306c	Z75214	similar to human X-linked pest-containing transporter	634 nt from start of ORF
5	ECM2	Z35934	involved in cell wall and plasma membrane biogenesis	268 nt from beginning of ORF

5	SCY1	Z72605	suppressor of GTPase mutant	189 nt from end of ORF
5	YDL057w	Z74105	hypothetical protein	58 nt after end of ORF
6	YNL187w	Z71463	hypothetical protein	14 nt from end of ORF
6	YPR105c	U32445	hypothetical transmembrane-spanning protein	444 nt from end of ORF
6	YAT1	X74553	carnitine acetyl transferase; mitochondrial transmembrane protein	363 nt from start of ORF
7	YLL013c	Z73118	similar to <i>Drosophila</i> pumilio protein	137 nt after beginning of ORF
7	TFC6	U28372	transcription factor; IIIc subunit Tau 91	345 nt after beginning of PRF
7	YLR376c	U19103	hypothetical transmembrane-spanning protein	526 nt past beginning of ORF
7	YBR203w	Z36072	hypothetical protein	1310 nt past ORF start
7	YGR257c	X99228	hypothetical protein with mitochondrial energy transfer protein signature	68 nt past ORF start
7	MIP1	Z28134	mitochondrial intermediate peptidase; transmembrane-spanning sequence	300 nt from end of ORF

7	YNL033w	Z71309	hypothetical transmembrane-spanning protein	615 nt past beginning of ORF
7	NUM1	Z50046	nuclear migration protein	6000 nt from start and 2000 nt from end of ORF
7	YOL092w	Z74834	protein similar to YBR147; transmembrane-spanning sequence	69 nt from start of ORF
7	SWI1	U33335	component of SWI/SNF global transcriptional activator complex	1600 nt from start of ORF
7	RFI2	Z49919	chromatin assembly complex, subunit p90	296 nt before start of ORF
7	YPR121w	U40828	similar to <i>B. subtilis</i> transcriptional activator tenA	152 nt past beginning of ORF

EXAMPLE 3

Identification of Riboactivators from "R40" library

10 *Results*

We wanted to prepare an RNA library that was not constrained, as is the above-described R10 library, by having all of its members contain the same base stem. Also, we were interested in preparing a library with a longer region of variability. Szostak and Ellington have recommended the use of RNAs 30-60 nts in length for formation of complex

structures such as multiple stem-loops, bulges, pseudoknots, and combinations thereof (Szostak et al. In *The RNA World* (Gesteland et al., eds), Cold Spring Harbor Laboratory Press, Cold Springs Harbor, NY, pp. 511-33. We therefore designed an oligonucleotide containing 40 randomized nucleotides flanked by the same sequences that flanked the stem-loop structure in the R10 library, so that the same primers could be used to amplify the R40 library as were used to amplify the R10 library. The R40 oligonucleotide has the sequence 5'-

CTCTGGGAGCTGCGATTGGCAGAATTCCGGCTAGAACTAGTGGATCCCCC>NNNNN
NNNGGGCAGCTTGCATGCCTG
CAGGTCGACTCTAGAAAACATGAGGATCACCC (SEQ ID NO:17). The R40 library will then be transformed into yeast and screened as was the R10 library.

EXAMPLE 4

Identification of a Riboregulator Interaction Target

Materials and Methods

GEL MOBILITY SHIFT ASSAYS: Yeast nuclear extract was prepared according to standard procedures and was stored in Buffer A (25 mM Tris pH 7.6, 5 mM MgCl₂, 0.1 mM EDTA pH 8.0, 80 mM KCl, 10% glycerol, 1.0 mM DTT, 0.48M (NH₄)₂SO₄, 1mM ZnCl). Radiolabeled riboactivator number 7 and control RNA number 10 were prepared in the same buffer. Each RNA was incubated with yeast nuclear extract for 10 minutes at room temperature and the mixtures were separated on an acrylamide gel under non-denaturing conditions.

NORTHWESTERN ASSAYS: Northwestern blotting was performed according to Kwon et al. (*Dev. Biol.* 158:90, 1993). Briefly, 5-60 µg of protein extract was separated by SDS/PAGE and transferred to PVDF membranes (Biorad). Proteins were allowed to renature and then membranes were probed with radiolabeled number 7 riboactivator loop sequence
5 (CCCGGGUGCUGGAUCACCCGGG; SEQ ID NO:26). After extensive washings, the filters were exposed to X-ray film so that protein-RNA interactions were detected.

Results

Our gel mobility shift assays indicated that riboactivator number 7, but not control RNA number 10, participated in a high molecular weight complex when incubated in yeast nuclear extract. Some complexes still formed when denatured extract was employed.

Northwestern analysis demonstrated that riboactivator number 7 bound to a protein in yeast nuclear extracts that was the size of yeast TBP (Figure 3). Further analyses with purified proteins revealed that number 7 interacts with yeast TBP, but not with yeast TFIID
15 lacking TBP, with yeast RNA polymerase II holoenzyme, or with mammalian TFIID (Figure 4). The Keene RNA, which does not activate transcription (see Example 2 above), also appears to bind to a protein in yeast nuclear extract that is the same size as TBP.

Other Embodiments

20 Those of ordinary skill in the art will recognize that the foregoing constitutes a description merely of certain preferred embodiments of the invention and is not intended to define or limit the scope of the following claims. Various changes, substitutions,

Case	Age	Sex	Site	Pathologic	Survival	Ref.
1	55	M	Stomach	Adenocarcinoma	10 mo	[1]
2	62	F	Stomach	Adenocarcinoma	12 mo	[2]
3	68	M	Stomach	Adenocarcinoma	15 mo	[3]
4	72	F	Stomach	Adenocarcinoma	18 mo	[4]
5	75	M	Stomach	Adenocarcinoma	20 mo	[5]
6	78	F	Stomach	Adenocarcinoma	22 mo	[6]
7	80	M	Stomach	Adenocarcinoma	24 mo	[7]
8	82	F	Stomach	Adenocarcinoma	26 mo	[8]
9	85	M	Stomach	Adenocarcinoma	28 mo	[9]
10	88	F	Stomach	Adenocarcinoma	30 mo	[10]
11	90	M	Stomach	Adenocarcinoma	32 mo	[11]
12	92	F	Stomach	Adenocarcinoma	34 mo	[12]
13	95	M	Stomach	Adenocarcinoma	36 mo	[13]
14	98	F	Stomach	Adenocarcinoma	38 mo	[14]
15	100	M	Stomach	Adenocarcinoma	40 mo	[15]
16	102	F	Stomach	Adenocarcinoma	42 mo	[16]
17	105	M	Stomach	Adenocarcinoma	44 mo	[17]
18	108	F	Stomach	Adenocarcinoma	46 mo	[18]
19	110	M	Stomach	Adenocarcinoma	48 mo	[19]
20	112	F	Stomach	Adenocarcinoma	50 mo	[20]
21	115	M	Stomach	Adenocarcinoma	52 mo	[21]
22	118	F	Stomach	Adenocarcinoma	54 mo	[22]
23	120	M	Stomach	Adenocarcinoma	56 mo	[23]
24	122	F	Stomach	Adenocarcinoma	58 mo	[24]
25	125	M	Stomach	Adenocarcinoma	60 mo	[25]
26	128	F	Stomach	Adenocarcinoma	62 mo	[26]
27	130	M	Stomach	Adenocarcinoma	64 mo	[27]
28	132	F	Stomach	Adenocarcinoma	66 mo	[28]
29	135	M	Stomach	Adenocarcinoma	68 mo	[29]
30	138	F	Stomach	Adenocarcinoma	70 mo	[30]
31	140	M	Stomach	Adenocarcinoma	72 mo	[31]
32	142	F	Stomach	Adenocarcinoma	74 mo	[32]
33	145	M	Stomach	Adenocarcinoma	76 mo	[33]
34	148	F	Stomach	Adenocarcinoma	78 mo	[34]
35	150	M	Stomach	Adenocarcinoma	80 mo	[35]
36	152	F	Stomach	Adenocarcinoma	82 mo	[36]
37	155	M	Stomach	Adenocarcinoma	84 mo	[37]
38	158	F	Stomach	Adenocarcinoma	86 mo	[38]
39	160	M	Stomach	Adenocarcinoma	88 mo	[39]
40	162	F	Stomach	Adenocarcinoma	90 mo	[40]
41	165	M	Stomach	Adenocarcinoma	92 mo	[41]
42	168	F	Stomach	Adenocarcinoma	94 mo	[42]
43	170	M	Stomach	Adenocarcinoma	96 mo	[43]
44	172	F	Stomach	Adenocarcinoma	98 mo	[44]
45	175	M	Stomach	Adenocarcinoma	100 mo	[45]
46	178	F	Stomach	Adenocarcinoma	102 mo	[46]
47	180	M	Stomach	Adenocarcinoma	104 mo	[47]
48	182	F	Stomach	Adenocarcinoma	106 mo	[48]
49	185	M	Stomach	Adenocarcinoma	108 mo	[49]
50	188	F	Stomach	Adenocarcinoma	110 mo	[50]
51	190	M	Stomach	Adenocarcinoma	112 mo	[51]
52	192	F	Stomach	Adenocarcinoma	114 mo	[52]
53	195	M	Stomach	Adenocarcinoma	116 mo	[53]
54	198	F	Stomach	Adenocarcinoma	118 mo	[54]
55	200	M	Stomach	Adenocarcinoma	120 mo	[55]
56	202	F	Stomach	Adenocarcinoma	122 mo	[56]
57	205	M	Stomach	Adenocarcinoma	124 mo	[57]
58	208	F	Stomach	Adenocarcinoma	126 mo	[58]
59	210	M	Stomach	Adenocarcinoma	128 mo	[59]
60	212	F				

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Jarrell Ph.D., Kevin A.
Saha Ph.D., Shamol
Ptashne Ph.D., Mark

(ii) TITLE OF INVENTION: NOVEL TRANSCRIPTIONAL REGULATORS AND
USES THEREFOR

(iii) NUMBER OF SEQUENCES: 26

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Choate, Hall & Stewart
(B) STREET: 53 State Street
(C) CITY: Boston
(D) STATE: MA
(E) COUNTRY: USA
(F) ZIP: 02109

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: US
(B) FILING DATE: 26-AUG-1998
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Jarrell Ph.D., Brenda H.
(B) REGISTRATION NUMBER: 39,223
(C) REFERENCE/DOCKET NUMBER: 0347941-0031

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (617) 248 5000
(B) TELEFAX: (617) 248 4000

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 140 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(vii) IMMEDIATE SOURCE:

(B) CLONE: Oligo 2, used to produce R10 library

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CTCTGGGAGC TGCATTGGC AGAATTCCGG CTAGAACTAG TGGATCCCC GGGCGAGGCT 60

TATCCNNNNN NNNNNGGATG TGCTGACCCC GGGCAGCTTG CATGCCTGCA GGTCGACTCT 120

5 AGAAAACATG AGGATCACCC 140

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(vii) IMMEDIATE SOURCE:

- (B) CLONE: Oligo 1, used to create R10 library

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2.

CTCTGGGAGC TGCATTGGC 20

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(vii) IMMEDIATE SOURCE:

- (B) CLONE: Oligo 3 used to create R10 library

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GGGTGATCCT CATGTTTCT 20

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: other nucleic acid

(vii) IMMEDIATE SOURCE:

- (B) CLONE: Riboactivator consensus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

UGCDGGHNMD 10

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(vii) IMMEDIATE SOURCE:

(B) CLONE: Riboactivator 1 sequence

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

UGCGGGUACG 10

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(vii) IMMEDIATE SOURCE:

(B) CLONE: Riboactivator number 2 sequence

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

UUGCUGGCGA 10

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(vii) IMMEDIATE SOURCE:

(B) CLONE: Riboactivator 3 sequence

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

UGC GGGUCAU 10

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(vii) IMMEDIATE SOURCE:

(B) CLONE: Riboactivator 4 sequence

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

UGC GGGUUCG 10

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(vii) IMMEDIATE SOURCE:

(B) CLONE: Ribactivator 5 sequence

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

UGC GGGAUCA 10

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(vii) IMMEDIATE SOURCE:

(B) CLONE: Riboactivator 6 sequence

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

UGCAGGUUCG 10

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(vii) IMMEDIATE SOURCE:

(B) CLONE: Riboactivator 7 sequence

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

UGCUGGAUCA 10

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(vii) IMMEDIATE SOURCE:

(B) CLONE: Riboactivator 8 sequence

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

UUGCUGGCGA 10

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(vii) IMMEDIATE SOURCE:

(A) LIBRARY: Non-riboactivator 3 sequence

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

CACGGTAAGT 10

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(vii) IMMEDIATE SOURCE:

(B) CLONE: Non-riboactivator 6 sequence

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

CAAAGACAGG 10

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(vii) IMMEDIATE SOURCE:

(B) CLONE: Non-riboactivator 8 sequence

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

GGCTGGTGGT 10

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 9 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(vii) IMMEDIATE SOURCE:

(B) CLONE: Non-riboactivator 10 sequence

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GTAGAGCGA 9

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 140 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(vii) IMMEDIATE SOURCE:

(B) CLONE: R40 oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17.

CTCTGGGAGC TCGATTGGC AGAATTCCGG CTAGAACTAG TGGATCCCC NNNNNNNNNN 60
NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN GGCGAGCTTG CATGCCTGCA GGTGACTCT 120
AGAAAACATG AGGATCACCC 140

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 40 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(vii) IMMEDIATE SOURCE:

(B) CLONE: Keene-1 oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

CCGGGCGAGG CTTATCCTGG TGGAGCAGGA TGTGCTGACC 40

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 40 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(vii) IMMEDIATE SOURCE:

(B) CLONE: Keene-2 oligonucleotide

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

CCGGGGTCAG CACATCCTGC TCCACCAGGA TAAGCCTCGC 40

10 (2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 59 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

15 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

20 (vii) IMMEDIATE SOURCE:

(B) CLONE: Tar-1 oligonucleotide

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

CCGGGTCTCT CTGGTTAGAC CAGATCTGAG CCTGGGAGCT CTCTGGCTAA CTAGAGAAC 59

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 59 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

30 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

40 (vii) IMMEDIATE SOURCE:

(B) CLONE: Tar-2 oligonucleotide

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

CCGGGTTCTC TAGTTAGCCA GAGAGCTCCC AGGCTCAGAT CTGGTCTAAC CAGAGAGAC 59

(2) INFORMATION FOR SEQ ID NO:22:

50 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 59 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

55 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

60 (vii) IMMEDIATE SOURCE:

(B) CLONE: 5/Tar-1 oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

CCGGGTCTCT CTGGTTAGAC CAGATCTGAG CCGGGATGCT CTCTGGCTAA CTAGAGAAC 59

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 59 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(vii) IMMEDIATE SOURCE:

(B) CLONE: 5/Tar-2 oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

CCGGGTTCTC TAGTTAGCCA GAGAGCATCC CGGCTCAGAT CTGGTCTAAC CAGAGAGAC 59

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 16 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(vii) IMMEDIATE SOURCE:

(B) CLONE: 7/Sma-1 oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

CCGGGTGCTG GATCAC 16

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 16 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(vii) IMMEDIATE SOURCE:

(B) CLONE: 7/Sma-2 oligonucleotide

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

CCGGGTGATC CAGCAC 16

10 (2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

15 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

20 (vii) IMMEDIATE SOURCE:

(B) CLONE: Probe of riboactivator 7 loop

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

CCCGGGUGCU GGAUCACCCG GG 22

Claims

1. A transcriptional regulator comprised of RNA.
2. A transcriptional regulator comprising:
5 a DNA-binding moiety; and
an RNA linked to the DNA binding moiety, the RNA having transcriptional regulatory activity.
3. The transcriptional regulator of claim 2 wherein the DNA-binding moiety is selected
10 from the group consisting of nucleic acids, polypeptides, intercalation compounds, and chemicals that demonstrate specific DNA binding.
4. The transcriptional regulator of claim 2 wherein the regulatory RNA is characterized
15 by an ability, when recruited to a DNA site operationally linked to a promoter, to activate transcription from that promoter at least two-fold.
5. The transcriptional regulator of claim 2 wherein the regulatory RNA is characterized
20 by an ability, when recruited to a DNA site operationally linked to a promoter, to activate transcription from that promoter to a level at least half that observed when the promoter is activated by Gal4 bound to a similarly-positioned site.
6. The transcriptional regulator of any one of claims 2, 4, or 5, wherein the regulatory RNA has a structure comprising a stem-loop.

7. The transcriptional regulator of claim 6 wherein the stem includes at least about 6 base pairs.
8. The transcriptional regulator of claim 6 wherein the stem includes at least about 10 basepairs.
9. The transcriptional regulatory of claim 7 wherein the regulatory RNA has a sequence comprising 5'-UGC(G>U>A)GG(U>A>C)(U>ACG)(C>A)(G>A>U)-3' (SEQ ID NO:4).
10. The transcriptional regulator of claim 1 or claim 2, which transcriptional regulator, when recruited to a site operationally linked to a promoter, increases transcription from that promoter.
11. The transcriptional regulator of claim 1 or claim 2, which transcriptional regulator, when recruited to a site operationally linked to a promoter, decreases transcription from that promoter.
12. The transcriptional regulator of claim 1 or claim 2, which transcriptional regulator affects transcription initiation.
13. The transcriptional regulator of claim 1 or claim 2, which transcriptional regulator affects elongation.

14. The transcriptional regulator of claim 1 or claim 2, which transcriptional regulator affects a process selected from the group consisting of reinitiation, termination, and pausing.

5 15. The transcriptional regulator of claim 1 or claim 2, which transcriptional regulator is active in one or more cell type selected from the group consisting of bacterial cells, yeast cells, mammalian cells, insect cells, plant cells, reptile cells, celenorate cells, and protozoan cells.

10 16. The transcriptional regulator of claim 15 wherein the regulator is active in yeast, mouse, or human cells.

17. The transcriptional regulator of claim 16 wherein the regulator is active in yeast and human cells.

15 18. The transcriptional regulator of claim 1 or claim 2 wherein the regulator is active at more than one gene in a given cell.

19. The transcriptional regulator of claim 10 wherein the regulator's activity is squelched in yeast cells by over-expression of Ga14.

20 20. The transcriptional regulator of claim 10 wherein the regulator functions as an acidic activator.

21. The transcriptional regulator of claim 1 or claim 2, which transcriptional regulator is constitutively active.

22. The transcriptional regulator of claim 1 or claim 2, which transcriptional regulator is conditionally active.

23. An RNA transcriptional regulator identified by a method comprising steps of:
providing a library of RNA molecules linked to an RNA comprising recruiting moiety;

expressing the linked library of RNA molecules in a cell that also expresses an interacting moiety linked to a DNA binding moiety that specifically recognizes a site operatively linked to a promoter directing expression of a detectable gene, which interacting moiety associates with the recruiting moiety;

detecting an increase or decrease in expression of the detectable gene; and

designating those RNA molecules present in cells in which expression of the detectable gene is increased or decreased as riboregulators.

24. A method of identifying RNA transcriptional regulators, the method comprising steps of:

providing a population of RNA molecules;

delivering the RNA molecules to a location operationally linked to a promoter; and

identifying those RNA molecules within the population that alter the rate or amount of transcription from the promoter.

25. The method of claim 24 wherein the step of identifying comprises identifying those RNA molecules that effect at least a two-fold change in the rate or extent of transcription from the promoter.

5 26. The method of claim 24 wherein the step of identifying comprises identifying those RNA molecules that effect at least a five-fold change in the rate or extent of transcription from the promoter.

10 27. The method of claim 24 wherein the step of identifying comprises identifying those RNA molecules that effect at least a ten-fold change in the rate or extent of transcription from the promoter.

15 28. The method of claim 24 where in the step of identifying comprises identifying those RNA molecules that effect at least a one hundred-fold change in the rate or extent of transcription from the promoter.

20 29. The method of claim 24 where in the step of identifying comprises identifying those RNA molecules that effect at least a one thousand-fold change in the rate or extent of transcription from the promoter.

30. A therapeutic composition comprising:
an RNA molecule characterized by an ability to alter transcription from a promoter when recruited to a site operatively linked to that promoter; and
a pharmaceutically acceptable carrier.

31. A method of treating an individual suffering from a disorder whose symptoms are alleviated or cured by effecting a change in expression of a gene, the method comprising steps of:

identifying an individual suffering from a disorder whose symptoms are alleviated or
5 cured by effecting a change in expression of a gene; and

administering to the individual an RNA molecule characterized in that, when the RNA molecule is recruited to a site operationally linked to the gene promoter, it effects the change in expression of the gene.

32. A method of identifying a target RNA that interacts with a test RNA, the method comprising steps of:

providing a first hybrid RNA molecule comprising a riboregulator linked to a test RNA;

providing a library of second hybrid RNA molecules, each of which comprises a
15 potential target RNA linked to an interacting RNA;

providing a third hybrid polypeptide molecule comprising an interacting polypeptide, which interacting polypeptide associates with the interacting RNA, linked to a DNA binding moiety, which DNA binding moiety binds to a site operationally linked to a promoter directing expression of a detectable gene;

20 expressing the first, second, and third hybrids in a cell also containing the gene under control of the promoter and operationally linked to the site;

detecting those cells in which expression of the gene is altered; and

classifying the potential target RNA of the library member in the detected cell as an RNA that interacts with the test RNA.

33. A method of identifying a target RNA that interacts with a test RNA, the method comprising steps of:

providing a library of first hybrid RNA molecules, each of which comprises a riboregulator linked to a potential target RNA;

5 providing a second hybrid RNA molecule, comprising a test RNA linked to an interacting RNA;

providing a third hybrid polypeptide molecule comprising an interacting polypeptide, which interacting polypeptide associates with the interacting RNA, linked to a DNA binding moiety, which DNA binding moiety binds to a site operationally linked to a promoter directing expression of a detectable gene;

expressing the first, second, and third hybrids in a cell also containing the gene under control of the promoter and operationally linked to the site;

detecting those cells in which expression of the gene is altered; and

classifying the potential target RNA of the library member in the detected cell as an RNA that interacts with the test RNA.

34. A method of identifying a target protein that interacts with a test RNA, the method comprising steps of:

providing a first hybrid RNA molecules, comprising a riboregulator linked to a test RNA;

providing a library of second hybrid polypeptide molecules, each of which comprises a potential target polypeptide linked to a DNA binding polypeptide, which DNA binding polypeptide binds to a site operationally linked to a promoter directing expression of a detectable gene;

expressing the first and second third hybrids in a cell also containing the gene under control of the promoter and operationally linked to the site;

detecting those cells in which expression of the gene is altered; and

classifying the potential target polypeptide of the library member in the detected cell

5 as a target polypeptide that interacts with the test RNA.

35. A method of identifying a target RNA that interacts with a test polypeptide, the method comprising steps of:

providing a library of first hybrid RNA molecules, each of which comprises a riboregulator linked to a potential target RNA;

providing a second hybrid polypeptide molecule comprising a test polypeptide linked to a DNA binding moiety, which DNA binding moiety binds to a site operationally linked to a promoter directing expression of a detectable gene;

expressing the first and second hybrids in a cell also containing the gene under control of the promoter and operationally linked to the site;

detecting those cells in which expression of the gene is altered; and

classifying the potential target RNA of the library member in the detected cell as a target RNA that interacts with the test polypeptide.

36. An RNA linker molecule comprising a first portion that interacts with a first interaction partner and a second portion that interacts with a second interaction partner.




FIGURE 1




FIGURE 2

3 / 4

YNE





FIGURE 3

1 2 3 4 5

33 K —



Lane 1 Marker
 Lane 2 Mammalian TFIID
 Lane 3 Yeast TBP
 Lane 4 Yeast TFIID (- TBP)
 Lane 5 Yeast Pol II holoenzyme

FIGURE 1

DECLARATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

NOVEL TRANSCRIPTIONAL REGULATORS AND USES THEREFOR

the specification of which (I authorize Choate, Hall & Stewart to check one of the following, three choices, and fill in the blanks, if applicable):

_____ is attached hereto

_____ was filed on _____ as Application
Serial No. _____ and amended on _____ (if applicable).

X was filed as PCT international application No. PCT/US98/17691
on August 26, 1998 and was amended under PCT Article 19
on _____ (if applicable).

I hereby state that I have reviewed and understood the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledged the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s):

Priority Claimed

(Number)	(Country)	(Day/Month/Year/Filed)	Yes	No

(Number)	(Country)	(Day/Month/Year/Filed)	Yes	No

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or PCT international application(s) designating the United States of America

0976646-011002

listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.) (filing date) (status-patented, pending, abandoned)

PCT Applications designating the United States:

(PCT Appl. No.) (U.S.S.N.) (status-patented, pending, abandoned)

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national filing date of this application.

Provisional Application(s):

60/056.857 August 27, 1997 pending
Application Number Filing Date Status

Application Number Filing Date Status

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United State Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Full name of first inventor: Kevin A. Jarrell

Inventor's signature: _____ Date: _____

Residence: 3 Acorn Lane, Lincoln, MA 01773

Citizenship: U.S.A.

Post Office Address: same

Full name of second inventor: Samol Saha

Inventor's signature: _____

Date: _____

Residence: 24 Sunset Road, Arlington, MA 02474

Citizenship: Swedish

Post Office Address: same

Full name of third inventor: Mark Ptashne

Inventor's signature: _____

Date: _____

Residence: 1075 Park Avenue, New York, NY 10120

Citizenship: U.S.A.

Post Office Address: same

2000-03-17 01:57 PM

DECLARATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

NOVEL TRANSCRIPTIONAL REGULATORS AND USES THEREFOR

the specification of which (I authorize Choate, Hall & Stewart to check one of the following, three choices, and fill in the blanks, if applicable):

_____ is attached hereto

_____ was filed on _____ as Application
Serial No. _____ and amended on _____ (if applicable).

X was filed as PCT international application No. PCT/US98/17691
on August 26, 1998 and was amended under PCT Article 19
on _____ (if applicable).

I hereby state that I have reviewed and understood the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledged the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s):

Priority Claimed

_____ (Number)	_____ (Country)	_____ (Day/Month/Year/Filed)	_____ Yes	_____ No
-------------------	--------------------	---------------------------------	--------------	-------------

_____ (Number)	_____ (Country)	_____ (Day/Month/Year/Filed)	_____ Yes	_____ No
-------------------	--------------------	---------------------------------	--------------	-------------

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or PCT international application(s) designating the United States of America

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or PCT international application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

<u> </u> (Application Serial No.)	<u> </u> (filing date)	<u> </u> (status-patented, pending, abandoned)
---	--	--

<u> </u> (Application Serial No.)	<u> </u> (filing date)	<u> </u> (status-patented, pending, abandoned)
---	--	--

PCT Applications designating the United States:

<u>PCT/US98/17691</u> (PCT Appl. No.)	<u>August 27, 1998</u> (U.S.S.N.)	<u>nationalized</u> (status-patented, pending, abandoned)
--	--------------------------------------	--

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national filing date of this application.

Provisional Application(s):

<u>60/056.857</u> (Application Serial No.)	<u>August 27, 1997</u> (filing date)	<u>expired</u> (status-patented, pending, abandoned)
---	---	---

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United State Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

200 Full name of second inventor: Samol Saha

Inventor's signature: *Samol Saha*

Date: 08-24-98

Residence: USA

Citizenship: SWEDISH

Post Office Address: 24 SUNSET RD. ARLINGTON, MA 02474
MA

Full name of third inventor: Mark Ptashne

Inventor's signature: _____

Date: _____

Residence: 1075 Park Avenue, New York, NY 10120

Citizenship: U.S.A.

Post Office Address: Same

DS1.424744.1

2007-09-14 14:00:00

Attorney Docket No. 0342941-0045 (HU 01431-97/ BU 9759)

DECLARATION

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

NOVEL TRANSCRIPTIONAL REGULATORS AND USES THEREFOR

the specification of which (I authorize Choate, Hall & Stewart to check one of the following, three choices, and fill in the blanks, if applicable):

_____ is attached hereto;

X was filed on August 26, 1998 as Application Serial No. 09/762,648 and amended on _____ (if applicable); or

_____ was filed as PCT international application No. _____, on _____ and was amended under PCT Article 19 on _____ (if applicable).

I hereby state that I have reviewed and understood the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledged the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed;

Prior Foreign Application(s):

Priority Claimed

_____ (Number)	_____ (Country)	_____ (Day/Month/Year/Filed)	Yes	No
-------------------	--------------------	---------------------------------	-----	----

_____ (Number)	_____ (Country)	_____ (Day/Month/Year/Filed)	Yes	No
-------------------	--------------------	---------------------------------	-----	----

listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.) (filing date) (status-patented, pending, abandoned)

PCT Applications designating the United States:

(PCT Appl. No.) (U.S.S.N.) (status-patented, pending, abandoned)

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national filing date of this application.

Provisional Application(s):

<u>60/056,857</u>	<u>August 27, 1997</u>	<u>pending</u>
Application Number	Filing Date	Status
<u>Application Number</u>	<u>Filing Date</u>	<u>Status</u>

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United State Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Full name of first inventor: Kevin A. Jawell

Inventor's signature: Kevin A. Jawell Date: 3/16/00

Residence: 3 Acorn Lane, Lincoln, MA 01773

Citizenship: U.S.A. MA

Post Office Address: same

Full name of first inventor: KEVIN A. JARRELL
Inventor's signature: _____ Date: _____
Residence: 3 Acorn Lane, Lincoln, MA 01773
Citizenship: United States
Post Office Address: Same

Full name of second inventor: SHAMOL SAHA
Inventor's signature: _____ Date: _____
Residence: 24 Sunset Road, Arlington, MA 02474
Citizenship: Sweden
Post Office Address: Same

Full name of third inventor: MARK PTASHNE
Inventor's signature: Mark Ptashne Date: 12/5/01
Residence: 9 E 79th Street, New York, NY 10021
Citizenship: United States NY
Post Office Address: Same

3289752_1.DOC